IONIS-FB-LRx

Dry AMD Therapeutic Pipeline Shows Promise with 70+ Companies Advancing Novel Therapies

4 months ago

• The dry age-related macular degeneration (AMD) therapeutic landscape is robust, with over 70 companies developing more than 80 therapies. • Key companies like Alkeus Pharmaceuticals and Roche are evaluating new drugs, aiming to improve the treatment options for dry AMD. • Recent clinical trials show promise, with Ocugen reporting positive data for OCU410 and Eyestem Research achieving a milestone in cell therapy for geographic atrophy. • Several therapies, including gene therapies and complement inhibitors, are in various clinical trial phases, addressing the unmet needs in dry AMD treatment.

Genentech's Gazyva Shows Positive Phase III Results in Lupus Nephritis Treatment

8 months ago

• Genentech's Gazyva met its primary endpoint in a Phase III REGENCY study, demonstrating statistically significant benefits for lupus nephritis patients. • Patients treated with Gazyva plus standard therapy achieved a higher rate of complete renal response at 76 weeks compared to standard therapy alone. • The study also showed statistically significant improvements in secondary endpoints, including reduced corticosteroid use and improved proteinuric response. • Gazyva targets disease-causing B cells, potentially preventing or delaying progression to end-stage kidney disease in lupus nephritis patients.

FDA Grants Full Approval to Travere's Filspari for IgA Nephropathy

9 months ago

• The FDA granted full approval to Travere Therapeutics' Filspari (sparsentan) for IgA nephropathy, allowing broader use for patients at risk of disease progression. • The approval was based on the PROTECT study, which demonstrated Filspari significantly slowed kidney function decline over two years compared to irbesartan. • Filspari is now positioned as a foundational, non-immunosuppressive treatment option, potentially replacing the current standard of care for IgAN patients. • The label update removes a specific urine protein level requirement, expanding the eligible patient population and increasing Filspari's market potential.

Dry AMD Therapeutic Pipeline Shows Promise with 70+ Companies Advancing Novel Therapies

Genentech's Gazyva Shows Positive Phase III Results in Lupus Nephritis Treatment

FDA Grants Full Approval to Travere's Filspari for IgA Nephropathy

Drug Development Updates